Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

NCT06483100 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elrantamab
DEVICE: clonoSEQ

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]